메뉴 건너뛰기




Volumn 107, Issue 12, 2007, Pages 25-33

Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)

Author keywords

Dementia; Galantamine; Parkinson's disease

Indexed keywords


EID: 38949177020     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (10)

References (42)
  • 1
    • 38949132621 scopus 로고    scopus 로고
    • Russian source
    • Russian source
  • 2
    • 38949134752 scopus 로고    scopus 로고
    • Russian source
    • Russian source
  • 3
    • 38949148189 scopus 로고    scopus 로고
    • Russian source
    • Russian source
  • 4
    • 38949160713 scopus 로고    scopus 로고
    • Russian source
    • Russian source
  • 5
    • 0032916601 scopus 로고    scopus 로고
    • Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease
    • Aarsland D., Larsen J.P., Cumming J.L. et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease. Arch Neurol 1999; 56: 3: 595-601.
    • (1999) Arch Neurol , vol.56 , Issue.3 , pp. 595-601
    • Aarsland, D.1    Larsen, J.P.2    Cumming, J.L.3
  • 6
    • 0035957311 scopus 로고    scopus 로고
    • Risk of dementia in Parkinson's Disease: A community-based prospective study
    • Aarsland D., Andersen K., Larsen J. P. et al. Risk of dementia in Parkinson's Disease: A community-based prospective study. Neurology 2001; 56: 6: 730-736.
    • (2001) Neurology , vol.56 , Issue.6 , pp. 730-736
    • Aarsland, D.1    Andersen, K.2    Larsen, J.P.3
  • 7
    • 0142091310 scopus 로고    scopus 로고
    • Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia
    • Aarsland D., Hutchinson M., Larsen J.P. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriat Psychiat 2003; 18: 10: 937-941.
    • (2003) Int J Geriat Psychiat , vol.18 , Issue.10 , pp. 937-941
    • Aarsland, D.1    Hutchinson, M.2    Larsen, J.P.3
  • 8
    • 0033668441 scopus 로고    scopus 로고
    • Delusions associated with elevated muscarinic binding in dementia with Lewy bodies
    • Bollard C., Piggott M., Johnson M. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000; 48: 6: 868-876.
    • (2000) Ann Neurol , vol.48 , Issue.6 , pp. 868-876
    • Bollard, C.1    Piggott, M.2    Johnson, M.3
  • 9
    • 0033572972 scopus 로고    scopus 로고
    • Caregiving as a risk factor for mortality: The Caregiver Health Effects Study
    • Beach S.R., Schulz R. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999; 282: 23: 2215-2219.
    • (1999) JAMA , vol.282 , Issue.23 , pp. 2215-2219
    • Beach, S.R.1    Schulz, R.2
  • 10
    • 0347385143 scopus 로고    scopus 로고
    • Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study
    • Bohnen N.I., Kaufer D.I., Ivanco L.S. et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 12: 1745-1748.
    • (2003) Arch Neurol , vol.60 , Issue.12 , pp. 1745-1748
    • Bohnen, N.I.1    Kaufer, D.I.2    Ivanco, L.S.3
  • 11
    • 32844471835 scopus 로고    scopus 로고
    • Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia
    • Bohnen N.I., Kaufer D.I., Hendrickson R. et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2005; 253: 2: 242-247.
    • (2005) J Neurol , vol.253 , Issue.2 , pp. 242-247
    • Bohnen, N.I.1    Kaufer, D.I.2    Hendrickson, R.3
  • 12
    • 0026355995 scopus 로고
    • Cognitive impairment and dementia in Parkinson's disease: A controlled study
    • Boyd J.L., Cruickshank C.A., Kenn C. W. et al. Cognitive impairment and dementia in Parkinson's disease: a controlled study. Psychol Med 1991; 21: 3: 911-921.
    • (1991) Psychol Med , vol.21 , Issue.3 , pp. 911-921
    • Boyd, J.L.1    Cruickshank, C.A.2    Kenn, C.W.3
  • 13
    • 0036040074 scopus 로고    scopus 로고
    • Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: A case series
    • Bullock R., Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18: 5: 258-264.
    • (2002) Curr Med Res Opin , vol.18 , Issue.5 , pp. 258-264
    • Bullock, R.1    Cameron, A.2
  • 14
    • 0035376503 scopus 로고    scopus 로고
    • Dopaminomimetic psychosis in Parkinson's disease: First symptom of early dementia?
    • Catalan-Alonso M.J., Del Val J. Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia? Rev Neurol 2001; 32: 11: 1085-1087.
    • (2001) Rev Neurol , vol.32 , Issue.11 , pp. 1085-1087
    • Catalan-Alonso, M.J.1    Del Val, J.2
  • 15
    • 0027985334 scopus 로고
    • The Neuropsychiatrie Inventory: Comprehensive assessment of psychopathology in dementia
    • Cummings J.L., Mega M., Gray K. et al. The Neuropsychiatrie Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 12: 2308-2314.
    • (1994) Neurology , vol.44 , Issue.12 , pp. 2308-2314
    • Cummings, J.L.1    Mega, M.2    Gray, K.3
  • 16
    • 0036625325 scopus 로고    scopus 로고
    • The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities
    • Da Cunha C., Angelucci M.E., Conteras N. S. et al. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell Mol Neurobiol 2002; 22: 3: 227-237.
    • (2002) Cell Mol Neurobiol , vol.22 , Issue.3 , pp. 227-237
    • Da Cunha, C.1    Angelucci, M.E.2    Conteras, N.S.3
  • 17
    • 0348048688 scopus 로고    scopus 로고
    • The role of olanzapine in Parkinsonian dopaminergic psychosis
    • Duran Ferreras E., Chacon J., Duran Quintana J.A. The role of olanzapine in Parkinsonian dopaminergic psychosis. Rev Neurol 2002; 35: 7: 691-696.
    • (2002) Rev Neurol , vol.35 , Issue.7 , pp. 691-696
    • Duran Ferreras, E.1    Chacon, J.2    Duran Quintana, J.A.3
  • 18
    • 0346749726 scopus 로고    scopus 로고
    • Edwards K.R., Hershey L., Wray L. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriat Cogn Disord 2004; 17: Supll 1: 40-48.
    • Edwards K.R., Hershey L., Wray L. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriat Cogn Disord 2004; 17: Supll 1: 40-48.
  • 19
    • 0028109336 scopus 로고
    • The US economic and social costs of Alzheimer's disease revisited
    • Ernst R.L., Hay J. W. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 8: 1261-1264.
    • (1994) Am J Public Health , vol.84 , Issue.8 , pp. 1261-1264
    • Ernst, R.L.1    Hay, J.W.2
  • 20
    • 0036276359 scopus 로고    scopus 로고
    • Donepezil in the treatment of hallucinations and delusions in Parkinson's disease
    • Fabbrini G., Barbanti P., Aurilia C. et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23: 1: 41-43.
    • (2002) Neurol Sci , vol.23 , Issue.1 , pp. 41-43
    • Fabbrini, G.1    Barbanti, P.2    Aurilia, C.3
  • 21
    • 0342424352 scopus 로고    scopus 로고
    • Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
    • Fenelon G., Mahieux F., Huon R. et al. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain 2000; 123: 7: 733-745.
    • (2000) Brain , vol.123 , Issue.7 , pp. 733-745
    • Fenelon, G.1    Mahieux, F.2    Huon, R.3
  • 23
    • 23644450772 scopus 로고    scopus 로고
    • Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients
    • Grossi D., Trojano L., Pellecchia M.T. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriat Psychiat 2005; 20: 7: 668-673.
    • (2005) Int J Geriat Psychiat , vol.20 , Issue.7 , pp. 668-673
    • Grossi, D.1    Trojano, L.2    Pellecchia, M.T.3
  • 24
    • 0036260184 scopus 로고    scopus 로고
    • Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: A 6-[18F]fluoro-L-dopa PET study
    • Ito K., Nagano-Saito A., Kato T. et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002; 125: 6: 1358-1365.
    • (2002) Brain , vol.125 , Issue.6 , pp. 1358-1365
    • Ito, K.1    Nagano-Saito, A.2    Kato, T.3
  • 25
    • 0842325101 scopus 로고    scopus 로고
    • Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
    • Leroi I., Brandt J., Reich S. G. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriat Psychiat 2004; 19: 1: 1-8.
    • (2004) Int J Geriat Psychiat , vol.19 , Issue.1 , pp. 1-8
    • Leroi, I.1    Brandt, J.2    Reich, S.G.3
  • 26
    • 33645834092 scopus 로고    scopus 로고
    • Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB
    • Mori T., Ikeda M., Fukuhara R. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 2006; 66: 6: 935-937.
    • (2006) Neurology , vol.66 , Issue.6 , pp. 935-937
    • Mori, T.1    Ikeda, M.2    Fukuhara, R.3
  • 27
    • 0032977982 scopus 로고    scopus 로고
    • Medication-induced hallucination and cerebral blood flow in Parkinson's disease
    • Okada K., Suyama N., Oguro H. et al. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J Neurol 1999; 246: 5: 365-368.
    • (1999) J Neurol , vol.246 , Issue.5 , pp. 365-368
    • Okada, K.1    Suyama, N.2    Oguro, H.3
  • 29
    • 0027208615 scopus 로고
    • Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease
    • Perry E., Irving D., Kerwin J.M. et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheitner Dis Assoc Disord 1993; 7: 2: 69-79.
    • (1993) Alzheitner Dis Assoc Disord , vol.7 , Issue.2 , pp. 69-79
    • Perry, E.1    Irving, D.2    Kerwin, J.M.3
  • 30
    • 0036868921 scopus 로고    scopus 로고
    • Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologie challenge with oral rivastigmine
    • Richard I.H., Justus A.W., Greig N.H. et al. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologie challenge with oral rivastigmine. Clin Neuropharmacol 2002; 25: 6: 296-299.
    • (2002) Clin Neuropharmacol , vol.25 , Issue.6 , pp. 296-299
    • Richard, I.H.1    Justus, A.W.2    Greig, N.H.3
  • 31
    • 0036063168 scopus 로고    scopus 로고
    • Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract 2002; 127: Supll 1: 20-36.
    • Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract 2002; 127: Supll 1: 20-36.
  • 32
    • 3142547230 scopus 로고    scopus 로고
    • Cholinergic enhancement of frontal lobe activity in mild cognitive impairment
    • Saykin A.J., Wishart H.A., Rabin L.A. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004; 127: 7: 1574-1583.
    • (2004) Brain , vol.127 , Issue.7 , pp. 1574-1583
    • Saykin, A.J.1    Wishart, H.A.2    Rabin, L.A.3
  • 33
    • 0030828946 scopus 로고    scopus 로고
    • Longitudinal analysis of multiple indicators of health decline among spousal caregivers
    • Shaw W.S., Patterson T.L., Semple S.J. Longitudinal analysis of multiple indicators of health decline among spousal caregivers. Ann Behav Med 1997; 19: 2: 101-109.
    • (1997) Ann Behav Med , vol.19 , Issue.2 , pp. 101-109
    • Shaw, W.S.1    Patterson, T.L.2    Semple, S.J.3
  • 34
    • 0036715245 scopus 로고    scopus 로고
    • Dementia in Parkinson disease: A proton magnetic resonance spectroscopy study
    • Summeifield C., Gomez-Anson B., Tolosa E. et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol 2002; 59: 9: 1415-1420.
    • (2002) Arch Neurol , vol.59 , Issue.9 , pp. 1415-1420
    • Summeifield, C.1    Gomez-Anson, B.2    Tolosa, E.3
  • 35
    • 0024372106 scopus 로고
    • Clock drawing in Alzheimer's disease: A novel measure of dementia severity
    • Sunderland T., Hill J.L., Mellow A.M. et al. Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J Am Geriat Soc 1989; 37: 5: 725-729.
    • (1989) J Am Geriat Soc , vol.37 , Issue.5 , pp. 725-729
    • Sunderland, T.1    Hill, J.L.2    Mellow, A.M.3
  • 36
    • 0034720864 scopus 로고    scopus 로고
    • A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group
    • Tariot P.N., Solomon P.R., Morris J.C. et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group Neurol 2000; 54: 12: 2269-2276.
    • (2000) Neurol , vol.54 , Issue.12 , pp. 2269-2276
    • Tariot, P.N.1    Solomon, P.R.2    Morris, J.C.3
  • 37
    • 33645749810 scopus 로고    scopus 로고
    • Visual dysfunction in Parkinson disease without dementia
    • Uc E.Y., Rizzo M., Anderson S.W. Visual dysfunction in Parkinson disease without dementia. Neurology 2005; 65: 12: 1907-1913.
    • (2005) Neurology , vol.65 , Issue.12 , pp. 1907-1913
    • Uc, E.Y.1    Rizzo, M.2    Anderson, S.W.3
  • 39
    • 12344253723 scopus 로고    scopus 로고
    • Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia
    • Van Marum R.J., Jansen P.A. Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia. Ned Tijdschr Geneeskd 2005; 149: 4: 165-167.
    • (2005) Ned Tijdschr Geneeskd , vol.149 , Issue.4 , pp. 165-167
    • Van Marum, R.J.1    Jansen, P.A.2
  • 40
    • 0037249095 scopus 로고    scopus 로고
    • Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease
    • Woods S.P., Troster A.I. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc 2003; 9: 1: 17-24.
    • (2003) J Int Neuropsychol Soc , vol.9 , Issue.1 , pp. 17-24
    • Woods, S.P.1    Troster, A.I.2
  • 41
    • 0037337815 scopus 로고    scopus 로고
    • Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer's and Parkinson's diseases
    • Zarow C., Lyness S.A., Mortimer I.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer's and Parkinson's diseases. Arch Neurol 2003; 60: 3: 337-341.
    • (2003) Arch Neurol , vol.60 , Issue.3 , pp. 337-341
    • Zarow, C.1    Lyness, S.A.2    Mortimer, I.A.3    Chui, H.C.4
  • 42
    • 4944239612 scopus 로고    scopus 로고
    • Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release
    • Zhang L., Zhou F., Dani J.A. Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release. Mol Pharmacol 2004; 66: 3: 538-544.
    • (2004) Mol Pharmacol , vol.66 , Issue.3 , pp. 538-544
    • Zhang, L.1    Zhou, F.2    Dani, J.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.